Effectiveness of an Interprofessional Program (Siscare) for Supporting Patients With Type 2 Diabetes.
Fiche du document
2023
- doi: 10.2337/ds21-0084
- issn: 1040-9165
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.2337/ds21-0084
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/36818412
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1040-9165
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_130FA874B8098
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Tsʻeu Tzʻu Ci Tse Medications Medicaments Prescription drugs Medicines (Drugs) Pharmaceuticals Medicine (Drugs)Citer ce document
N. Bawab et al., « Effectiveness of an Interprofessional Program (Siscare) for Supporting Patients With Type 2 Diabetes. », Serveur académique Lausannois, ID : 10.2337/ds21-0084
Métriques
Partage / Export
Résumé
To assess the effectiveness of an interprofessional support program (Siscare) that includes motivational interviews (patient-pharmacist), electronic monitoring (EM) of medications, patient-reported and clinical outcomes monitoring, and interactions with physicians for patients with type 2 diabetes in French-speaking Switzerland. This was a prospective, multicenter, observational cohort study using a hybrid implementation-effectiveness design. Individual daily adherence to at least one oral antidiabetic medication was measured by EM. A global adherence score was estimated by the product of a model-estimated implementation and a nonparametric estimate of persistence over time. Clinical outcomes (A1C, blood glucose, BMI, blood pressure, heart rate, and cholesterol levels) and quality of life (QoL) were analyzed over time using linear mixed-effect models. A total of 212 patients were included from 27 pharmacies; 120 patients (57%) were followed up for at least 15 months. In total, 140 patients (66%) were male, the mean age was 64 ± 11 years, and the mean number of chronic medications per patient at baseline was 5 ± 3. Of 178 patients who used EM, 95% (95% CI 92-99%) remained persistent at the end of the follow-up period. The percentage of persistent patients taking their medications appropriately (implementation) was stable during follow-up and was estimated to be 90% (95% CI 87-92%) at baseline and 88% (95% CI 84-91%) at month 15. At baseline, the mean A1C and BMI were 7.5% and 31 kg/m 2 , respectively, which decreased by 0.5% (P = 0.012) and 0.6 kg/m 2 (P = 0.017), respectively, after 15 months. QoL remained stable during follow-up. The program supports medication adherence and improves clinical outcomes, illustrating the overall preventive effect of coordinated care.
